A report back on Michell Mugglin's and Sebastian Verboeket's session Weight-gain under integrase-inhibitors: Is this real?
I must say, I was very surprised to find it was standing-room only at this session on INSTI effects on body weight. This more recent observation, that integrase-inhibitors, particularly the second generation drugs (dolutegravir, bictegravir), are associated with increases in body weight (Sax et al, Clin Infect Dis. 2019 Oct 14), has sparked a flurry of interest in this area.
These findings have left us with more questions than answers. How is body weight distributed? What mechanisms are involved? Is this a ‘true’ side-effect, or simply the effect of a ‘return to health’ phenomenon?